Original Article

Trends in Pharmacy Compounding for Women's Health in North Carolina: Focus on Vulvodynia

Authors: Susan H. Corbett, PharmD, Gary Cuddeback, PhD, MPH, Jasmine Lewis, BS, Swasan As-Sanie, MD, Denniz Zolnoun, MD, MPH

Abstract

Objectives: To identify trends in compounding pharmacies with a focus on women’s health and, more specifically, the types and combinations of medications used in the treatment of vulvodynia.

Methods: This survey study was conducted with 653 nonchain pharmacies that compound medications. Each pharmacy was asked to complete a 19-item online survey assessing general practice and common compounding indications, focusing on women’s health.

Results: Of the 653 pharmacies contacted, 200 (31%) responded to our survey. Women’s health issues ranked third (19%) among the common indications for compounding, preceded by otolaryngology (30%) and dermatology (28%). Of the medications compounded for women’s health, the most common indication was bioidentical hormone therapy (73%) followed closely by vaginal dryness (70%) and low libido (65%). Vulvodynia, or vulvar pain, was the fourth most common indication for compounding medication for women’s health issues (29%). Vulvovaginal infections were reported as an indication for compounding medications by 16% of respondents.

Conclusions: Vulvovaginal symptoms are a common indication for compounding medications in women’s health. Further research in understanding the rationale for using compounded medications, even when standard treatments are available for some of these symptoms (eg, vaginal dryness, vulvovaginal infections), is warranted.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Talsma J. Fungal meningitis outbreak kills 36. Drug Topics 2012;156:26-30.
 
2. Multistate outbreak of fungal meningitis and other infections. http://www.cdc.gov/hai/outbreaks/meningitis.html. Published September 6, 2013. Accessed September 17, 2013.
 
3. Paul R. New bill on pharmacy compounding stirs concern: Safe Drug Compounding Act of 2007. Drug Topics 2007;151:18.
 
4. King LD. FDA’s stand on compounding is bad for R. Ph.s and patients: a compounding leader takes issue with FDA’s position that compounding is the production of a new drug that nees to be approved. Drug Topics 2007;151:44.
 
5. Edwards L. New concepts in vulvodynia. Am J Obstet Gynecol 2003; 189:S24-S30.
 
6. MedicineNet. Definition of orphan disease. http://www.medterms.com/script/main/art.asp?articlekey=11418. Published March 19, 2012. Accessed January 7, 2014.
 
7. Haefner HK, Collins ME, Davis GD, et al. The vulvodynia guideline. J Low Genit Tract Dis 2005;9:40-51.
 
8. Grimes DA, Schulz KF. False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol 2012;120:920Y927.
 
9. Adams C, Cannell S. Women’s beliefs about ‘‘natural’’ hormones and natural hormone replacement therapy. Menopause 2001;8:433-440.
 
10. Kastango ES, Bradshaw BD. USP chapter 797: establishing a practice standard for compounding sterile preparations in pharmacy. Am J Health Syst Pharm 2004;61:1928-1238.
 
11. McPherson TB, Fontane PE, Jackson KD, et al. Prevalence of compounding in independent community pharmacy practice. J Am Pharm Assoc (2003) 2006;46:568-573.
 
12. Matheny C, Martin CM. Compounding pharmacy: old methods finding a new niche. Consult Pharm 2010;25:357-363.